Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City | Zendy

Marie Abdallah | Zendy; Olawole Olafisoye | Zendy; Christopher Cortes | Zendy; Carl Urban | Zendy; David Landman | Zendy; John Quale | Zendy

Open Access

Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City

Author(s) -

Marie Abdallah,

Olawole Olafisoye,

Christopher Cortes,

Carl Urban,

David Landman,

John Quale

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.04809-14

Subject(s) - acinetobacter baumannii , enterobacteriaceae , microbiology and biotechnology , multiple drug resistance , acinetobacter , enterobacteriaceae infections , biology , antibiotics , bacteria , escherichia coli , pseudomonas aeruginosa , genetics , gene

Eravacycline demonstratedin vitro activity against a contemporary collection of more than 4,000 Gram-negative pathogens from New York City hospitals, with MIC50 /MIC90 values, respectively, forEscherichia coli of 0.12/0.5 μg/ml,Klebsiella pneumoniae of 0.25/1 μg/ml,Enterobacter aerogenes of 0.25/1 μg/ml,Enterobacter cloacae 0.5/1 μg/ml, andAcinetobacter baumannii of 0.5/1 μg/ml. Activity was retained against multidrug-resistant isolates, including those expressing KPC and OXA carbapenemases. ForA. baumannii , eravacycline MICs correlated with increased expression of theadeB gene.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research